Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As the first product in XLifeSc's pipeline, TAEST16001 enables autologous T-cell transduced with a replication incompetent lentiviral vector to express NY-ESO-1-specific TCR.
Lead Product(s): TAEST16001
Therapeutic Area: Oncology Product Name: TAEST16001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: GenScript Biotech Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
This clinical trial project is China's first TCR-T project targeted at solid tumor therapy, marking a milestone in immunotherapy in China.
Lead Product(s): NY-ESO-1 TCR transduced T cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020